Status:
COMPLETED
Cupping and Serkangabin Versus Conventional Migraine Treatment
Lead Sponsor:
Birjand University of Medical Sciences
Conditions:
Migraine Headache
Eligibility:
All Genders
15-50 years
Phase:
PHASE4
Brief Summary
Migraine is the most common recurrent headache. Current therapy of migraine headache consists of multiple drug groups for control of attack and prophylaxis against recurrent attacks. Emerging alternat...
Detailed Description
In a randomized controlled trial investigators randomly assigned 76 patients with migraine to cupping therapy plus SERKANGABIN or to receive conventional medical treatment. The use of CAM in migraine ...
Eligibility Criteria
Inclusion
- migraine headache with or without aura
Exclusion
- uncontrolled hypertension
- ischemic heart disease
- cardiac arrhythmia or symptomatic Wolff-Parkinson-White syndrome
- previous stroke or transient ischemic attack
- severe liver or renal impairment
- any other severe or disabling medical condition
- history of alcohol or analgesic or psychotropic drug abuse
- contraindication to or known hypersensitivity to study drugs
- current use or use in the previous 2 weeks of MAO-inhibitors
- a pain disorder other than migraine as the primary presenting problem
- current psychological treatment, psychiatric disorder needing immediate or priority treatment
- current or planned breast feeding or pregnancy or unwillingness to use an established contraceptive method
- non compliance of patients
- not presenting at times determined for treatment and evaluation
Key Trial Info
Start Date :
June 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2011
Estimated Enrollment :
391 Patients enrolled
Trial Details
Trial ID
NCT01476930
Start Date
June 1 2008
End Date
October 1 2011
Last Update
November 24 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Birjand University of Medical Sciences,Valiasr Hospital
Birjand, South Khorasan Province, Iran, 9714815395